Vivimed Labs Ltd Plunges to Lower Circuit Amid Heavy Selling Pressure

Market Performance and Price Action

Vivimed Labs Ltd (Stock ID: 612893) closed at ₹7.32, down ₹0.25 or 3.3% from the previous close, reaching the maximum permissible daily loss limit of 5% on the equity series. The stock traded within a price band of ₹7.20 to ₹7.57, with total traded volume of approximately 34,387 shares (0.34387 lakhs) and a turnover of ₹0.0248 crore. This sharp fall contrasts with the broader market’s modest declines, with the Sensex down 0.84% and the pharmaceutical sector falling 0.97% on the same day.

Heavy Selling Pressure and Unfilled Supply

The plunge to the lower circuit was driven by heavy selling pressure, with a notable imbalance between supply and demand. Market participants reported panic selling, as investors rushed to exit positions amid concerns over the company’s near-term prospects. The unfilled supply at the lower circuit price level indicates that sellers overwhelmed buyers, preventing the stock from stabilising or recovering intraday.

Technical Indicators and Investor Participation

Technical analysis reveals that Vivimed Labs is trading below all key moving averages, including the 5-day, 20-day, 50-day, 100-day, and 200-day averages, signalling a sustained downtrend. Investor participation has also waned, with delivery volumes on 27 Feb 2026 falling by 40.29% compared to the 5-day average, reflecting reduced confidence and liquidity in the stock. Despite this, the stock remains liquid enough for small trade sizes, with 2% of the 5-day average traded value supporting transactions up to ₹0.01 crore.

Fundamental Context and Market Capitalisation

Vivimed Labs operates in the Pharmaceuticals & Drugs industry and is classified as a micro-cap company with a market capitalisation of ₹59.86 crore. The company’s Mojo Score currently stands at 24.0, with a Mojo Grade of Strong Sell, an upgrade from the previous Sell rating on 5 Feb 2026. This downgrade reflects deteriorating fundamentals and weak market sentiment, which have contributed to the stock’s recent underperformance.

Comparative Performance and Sectoral Impact

On 2 Mar 2026, Vivimed Labs underperformed its sector by 1.41%, with the stock’s 1-day return at -4.62% compared to the sector’s -0.97%. This divergence highlights the company’s specific challenges relative to its pharmaceutical peers. The broader market’s mild decline suggests that the stock’s sharp fall is driven more by company-specific factors than systemic market weakness.

Investor Sentiment and Outlook

The strong sell rating and low Mojo Score reflect a cautious outlook from analysts and market observers. The persistent downtrend and failure to hold above key moving averages indicate that the stock may continue to face downward pressure in the near term. Investors should be wary of the ongoing panic selling and unfilled supply, which could exacerbate volatility and limit recovery potential.

Liquidity and Trading Considerations

Despite the micro-cap status and relatively low market capitalisation, Vivimed Labs maintains sufficient liquidity for small-scale trades. However, the sharp decline and circuit hit may deter larger institutional investors, further constraining demand. Traders should monitor volume trends and delivery data closely to gauge shifts in investor participation and potential reversal signals.

Conclusion: Navigating the Downtrend

Vivimed Labs Ltd’s plunge to the lower circuit on 2 Mar 2026 underscores the challenges facing this micro-cap pharmaceutical stock. Heavy selling pressure, unfilled supply at the lower price band, and deteriorating technical indicators paint a cautious picture for investors. While the company’s fundamentals and market cap remain modest, the strong sell rating and recent price action suggest that investors should exercise prudence and closely monitor developments before considering exposure.

Given the current market dynamics, those holding the stock may want to reassess their positions, while prospective investors should seek superior opportunities with stronger fundamentals and more favourable technical setups.

Only Rs. 9,999 - Get MojoOne for 1 Year + 3 Months FREE (60% Off) Start Today